Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19, the company said. The new initiative of Novartis aims to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms of COVID-19 – a critical need in the absence of a vaccine or curative treatment.
Leishmaniasis patients in Eastern Africa may soon benefit from a new drug set to be developed by collaboration of Novartis, one of the biggest pharmaceuticals company and the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development organization.
By Andualem Sisay Gessesse – Novartis, a global healthcare company based in Switzerland, is set to introduce a new program to Ethiopia that aims to make affordable treatment of chronicle diseases in low and middle income countries.
The international political climate may be turning against globalization and threatening economic growth, but there is still a chance to channel money into sectors that can boost prosperity in poor countries, political and corporate leaders said.